CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
http://doi.org/10.5281/zenodo.4303701

Avalable online at: http://www.iajps.com *Research Article*

PLASMA TYROSINE AND THE INTERACTION OF TYROSINE WITH THE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND PAKISTANI RISK OF TYPE 2 DIABETES MELLITUS

[1]Dr Manzoor Hussain, [2]Waqar Arshad, [3]Muhammad Shawaiz Tariq

[1]Registrar, Medical A unit, MTI/Mardan Medical Complex, Mardan

[2]Senior House Officer Emergency Medicine South Tipperary General Hospital, Clonmel, Ireland

[3]Medical Officer, Dhigurah Health Centre Maldives

Article Received: October 2020 **Accepted:** November 2020 **Published: December** 2020

Abstract:

Aim: *Metabolomic markers can potentially improve the accuracy of prediction of existing hazard scores for type 2 diabetes mellitus. The current review has tested the relationship between plasma tyrosine and type 2 diabetes mellitus, with particular attention to distinguishing conceivable hazard thresholds for type 2 diabetes mellitus, and its intelligent impacts on low lipoprotein cholesterol (HDL-C) and fatty oil for type 2 diabetes mellitus.*

Methods: *From March 2019 to February 2020, we retrieved the clinical notes of 1,898 hospitalized patients with type 2 diabetes mellitus as cases and 1,522 non-diabetic controls who underwent annual clinical examinations at a similar tertiary consideration center in Lahore, Pakistan. Our current research was conducted at Jinnah Hospital, Lahore from March 2019 to February 2020. Relapse strategic reviews were conducted to achieve 95% chance proportions (OR) and 95% certainty intervals (CI). Confined cubic spline examination, established as part of the strategic relapse review, was used to distinguish conceivable tyrosine cut-off targets for type 2 diabetes mellitus. Substance-added cooperation was used to evaluate associations between high tyrosine and low HDL-C in patients with type 2 diabetes mellitus.*

Results: *Tyrosine levels for type 2 diabetes mellitus did not rise until 46 lmol/L and after this point, tyrosine levels rose rapidly with almost direct tyrosine expansion. In the unlikely hypothesis that 46 lmol/L was used to characterize elevated tyrosine, it was associated with an expanded OR for type 2 diabetes mellitus (modified OR 1.89, 96% CI 1.46-3.46). The presence of low HDL-C incredibly improved the ORs of tyrosine for type 2 diabetes mellitus from 1.11 (96% CI 0.83-1.53) to 57.12 (97% CI 35.97-867.23) with critical cooperation of added substances.*

Conclusion: *In Pakistani grown-ups, tyrosine >46 lmol/L was related with expanded chances of type 2 diabetes mellitus, which was dependent upon low HDL-C.*

Keywords: *Plasma tyrosine, high-density lipoprotein cholesterol, Jinnah Hospital, Lahore, Pakistan.*

Corresponding author:

Dr Manzoor Hussain,

Registrar, Medical A unit, MTI/Mardan Medical Complex, Mardan

QR code

Please cite this article in press Manzoor Hussain et al, ***Plasma Tyrosine And The Interaction Of Tyrosine With The High-Density Lipoprotein Cholesterol And Pakistani Risk Of Type 2 Diabetes Mellitus****., Indo Am. J. P. Sci, 2020; 07(12).*

INTRODUCTION:

Type 2 diabetes mellitus has become a strong load on limited clinical resources. In Pakistan, the inescapability of diabetes showed up at 13.7% in 2010, impacting around 114.7 million adults1. Type 2 diabetes mellitus begins from relationship between innate tendencies and biological elements [1]. Among the natural parts, overweight likewise, weight is acknowledged to expect a causal capacity in the growing load of type 2 diabetes mellitus [2]. Chunkiness, especially central power, every now and again appears in packs with insulin resistance, high greasy substance and low high-thickness lipoprotein cholesterol (HDL-C); that is, claimed metabolic condition. In spite of the way that type 2 diabetes mellitus is preventable by lifestyle modifications, it remains a test to exactly predict diabetes at singular levels [3]. Past animal tests found that insulin impediment was related with absorption of tyrosine, and raised tyrosine levels may quell the insulin hailing pathway, which is related to the improvement of type 2 diabetes mellitus. Similarly, it is acknowledged that there is an association among hyperglycemia and tyrosine nitration [4], suggesting that changed levels of tyrosine may reflect the degree of oxidative pressure or disturbance in people with diabetes or prediabetes conditions. Dependably, human assessments similarly observed that extended plasma gathering of tyrosine is connected with hyperglycemia9, and might be one of the indications of subclinical disturbance and safe enactment. The connection between tyrosine levels and the risk of type 2 diabetes mellitus was ground-breaking by character and study plans [5]. It is entrancing to observe that in spite of the way that plasma levels of various amino acids have been on and on associated with type 2 diabetes mellitus, tyrosine has the most grounded relationship with the occasion of type 2 diabetes mellitus, self-ruling of obesity. To our data, a few examinations did in Pakistani peoples attempted the relationship among tyrosine and type 2 diabetes mellitus.

METHODOLOGY:

In 2013, the metabolomics lab was set up, which offered metabolomic looks at to all patients including outpatients or inpatients, or then again those individuals at their prosperity evaluations who agreed to pay the cost. An amount of 71,020 patients having a metabolomics profile were assessed from March 2019 to February 2020, in Jinnah Hospital. Our current research was conducted at Jinnah Hospital, Lahore from March 2019 to February 2020. Among them, 1,898 patients were resolved to have type 2 diabetes mellitus, moreover, their electronic clinical records were recuperated. Patients developed <18 years, and lacking information on height, weight and circulatory strain were prohibited. Considering these dismissal rules, 1,034 diabetes patients examined by the 1999 World Wellbeing Organization's criteria17 or treated with antidiabetic drugs were remaining and were relegated to the case gathering. During this period, a total of 10,649 individuals without diabetes from the clinical center's catchment domains participated in a prosperity appraisal, and 6,489 of them without information on height, weight and circulatory strain were dismissed. Of the remaining 7,162 individuals, 1,522 individuals with metabolomic profiles assessed using a comparative system (developed >19 years) were recuperated and used as the benchmark gathering. Finally, we facilitated a crisis center based non-composed case–control concentrate with 2,554 individuals (1,034 cases and 1,524 controls) to address our assessment questions. The recuperated data in the cases included portion and anthropometric information, and current clinical factors, medicates besides, diabetes disarrays. The clinical limits included glycated hemoglobin, circulatory strain, lipid profile, plasma creatinine, urinary creatinine and egg whites. Diabetes complexities included coronary ailment, cerebrovascular ailment, diabetic retinopathy and diabetic nephropathy. The nuances use of prescriptions was recorded, including oral antidiabetic drugs and insulin, angiotensin-changing over compound inhibitors, angiotensin receptor blockers, and other antihypertensive meds, statins, and other lipid bringing down medications. The recuperated data in the benchmark bunch included section information, anthropometric information and lab looks at. In this clinical facility, standardized systems were used to measure anthropometric records. Individuals wore light pieces of clothing and no shoes. Stature and bodyweight were assessed to the nearest 0.6 cm and 0.2 kg, independently.

Table 1:

Variables	Non- type 2 diabetes mellitus (1,522) Mean/*n* (SD or %)	Type 2 diabetes mellitus (1,032) Mean/*n* (SD or %)	*P*-value
Age (years)	46.3 ± 13.7	57.2 ± 13.8	<0.001
Duration of diabetes (years)		5 (0–10)	
Duration of diabetes ≤2 years		401 (38.9%)	
Male sex	1,131 (74.3%)	549 (53.2%)	<0.001
Weight (kg)	73.6 ± 13.5	70.3 ± 13.2	<0.001
Height (cm)	169.7 ± 8.0	166.5 ± 8.2	<0.001
BMI (kg/m^2)	25.4 ± 3.5	25.3 ± 3.9	0.334
BMI < 18.5	23 (1.5%)	27 (2.6%)	
BMI ≥18.5 and <24	504 (33.1%)	354 (34.3%)	
BMI ≥24 and <28	653 (42.9%)	430 (41.7%)	
BMI ≥ 28	342 (22.5%)	221 (21.4%)	
SBP (mmHg)	130.9 ± 17.2	140.4 ± 24.0	<0.001
DBP (mmHg)	81.0 ± 11.6	82.5 ± 13.5	0.005
HDL-C (mmol/L)	1.55 ± 0.35	1.08 ± 0.35	<0.001
Male (HDL-C <1.0 mmol/L)	54 (3.6%)	224 (21.7%)	<0.001
Female (HDL-C <1.3 mmol/L)	40 (2.5%)	262 (25.4%)	
LDL-C (mmol/L)	3.06 ± 0.70	2.89 ± 1.01	<0.001
Triglyceride (mmol/L)	1.51 (1.02–2.35)	1.67 (1.11–2.38)	0.016
Tyrosine (μmol/L)	42.59 (34.74–52.00)	45.78 (36.70–56.27)	<0.001
<30 μmol/L	170 (11.2%)	102 (9.9%)	<0.001
≥30 to ≤46 μmol/L	745 (48.9%)	424 (41.1%)	
>46 μmol/L	607 (39.9%)	506 (49.0%)	
HbA1c (%)		9.6 ± 2.4	
Macrovascular complications			
Prior CHD		210 (20.4%)	
Prior stroke		199 (19.3%)	
Microvascular complications			
Diabetic retinopathy		162 (15.7%)	
Diabetic nephropathy		188 (18.2%)	
Diabetes medications			
Oral antidiabetic drugs		569 (55.1%)	
Insulin		772 (74.8%)	
Statins		370 (35.9%)	
Other lipid-lowering drugs		23 (2.2%)	
ACEIs		135 (13.1%)	
ARBs		134 (13.0%)	
Other antihypertensive drugs		309 (29.9%)	

Data are mean (standard deviation), median (interquartile range) or *n* (%). ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.

Figure 1:



RESULTS:

The 2,554 individuals made some mean memories of 52.8 years (SD 15.9 years), mean height of 168.4 cm (SD 9.3 cm), mean bodyweight of 72.3 kg (SD 13.4 kg) and mean BMI of 26.5 kg/m² (SD 4.7 kg/m²). Differentiated and their accomplices without diabetes, the cases had a more settled age, more restricted stature, higher systolic heartbeat and diastolic circulatory strain. They were will undoubtedly have lower levels of HDL-C what's more, LDL-C, yet more critical degrees of greasy substance and tyrosine. Patients with type 2 diabetes mellitus had a center of 5 years (25th to 75th: 0–10) of length of diabetes. Also, they had a mean glycated hemoglobin of 8.61% (SD 3.39%), and the inescapability of microvascular and microvascular affliction is showed up in Table 1. In multivariable assessment, tyrosine was connected with type 2 diabetes mellitus in a V-formed relationship. Obviously, at levels <30 lmol/L, tyrosine was alternately associated with type 2 diabetes mellitus in a for the most part direct manner, while at >32 lmol/L, the odds extent of tyrosine for type 2 diabetes mellitus started to diminish consistently, showing up at a nadir at 39 lmol/L and a short time later rapidly growing up to 48 lmol/L. Beginning there onwards, tyrosine was connected with type 2 diabetes mellitus nearly in a direct manner (Figure 1). In the current examination, 44.6% (n = 1,115) of individuals were characterized into the huge degree of tyrosine (>46 lmol/L) and 46.6% (n = 509) of the patients with a high tyrosine level had type 2 diabetes mellitus. Then again, 12.7% (n = 274) of individuals had low tyrosine (<30 lmol/L) and 38.6% (n = 103) of the individuals who had a low tyrosine level had type 2 diabetes mellitus.

Table 2:

high-density lipoprotein cholesterol for type 2 diabetes mellitus

	OR (95% CI)	*P*-value
Univariable independent model		
Tyr (per μmol/L)	1.02 (1.01–1.03)	<0.001
Multivariable independent model		
Tyr (per μmol/L)	1.03 (1.02–1.04)	<0.001
Univariable independent model		
<30 μmol/L	1.05 (0.80–1.39)	0.704
≥30 to ≤46 μmol/L	Reference	
>46 μmol/L	1.47 (1.24–1.73)	<0.001
Multivariable independent model†		
<30 μmol/L	1.35 (0.89–2.07)	0.163
≥30 to ≤46 μmol/L	Reference	
>46 μmol/L	1.88 (1.44–2.45)	<0.001
Univariable independent model		
Tyr ≤46 μmol/L & high HDL-C	Reference	
Tyr ≤46 μmol/L & low HDL-C	21.80 (15.68–30.29)	<0.001
Tyr >46 μmol/L & high HDL-C	1.28 (0.98–1.67)	0.072
Tyr >46 μmol/L & low HDL-C	54.35 (35.56–83.07)	<0.001
RERI	32.27 (9.84–54.71)	
AP	0.59 (0.40–0.79)	
S	2.63 (1.56–4.11)	
Multivariable independent model‡		
Tyr ≤46 μmol/L & high HDL-C	Reference	
Tyr ≤46 μmol/L & low HDL-C	18.23 (12.57–26.43)	<0.001
Tyr >46 μmol/L & high HDL-C	1.11 (0.82–1.51)	0.503
Tyr >46 μmol/L & low HDL-C	54.11 (33.96–86.22)	<0.001
RERI	35.78 (11.66–59.89)	
AP	0.66 (0.49–0.83)	
S	3.06 (1.82–5.17)	

†Adjusted for age, sex, body mass index, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglyceride. ‡Adjusted for age, sex, body mass index, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride and tyrosine (Tyr) <30 μmol/L. Significant elative

DISCUSSION:

We found that high plasma tyrosine was connected with type 2 diabetes mellitus in Pakistani patients with type 2 diabetes mellitus, likewise, tyrosine levels at ≥47 lmol/L were connected with an especially extended OR of type 2 diabetes mellitus [6]. In any case, its relationship with type 2 diabetes mellitus was sudden upon the presence of low HDL-C. A positive relationship among tyrosine and the peril of type 2 diabetes mellitus had been more than once point by

point in a couple of studies [7]. A little cross-sectional examination of 73 individuals who were fat or at high peril for type 2 diabetes mellitus showed that raised serum tyrosine levels were connected with extended insulin opposition. A colossal report in 9,500 Finnish men declared that plasma tyrosine was vehemently related with glycaemia [8]. The Framingham Offspring Studies in like manner found that tyrosine, gotten together with two other amino acids, was able to predict event type 2 diabetes mellitus11. Consistent with these disclosures, we saw a positive connection between high tyrosine and the extended OR of type 2 diabetes mellitus in Pakistani individuals, regardless of the way that tyrosine in the current individuals was basically lower than those reported in South Asians, even lower than Europeans [9]. Tyrosine is locked in with gluconeogenesis and glucose transport. The overabundance of tyrosine is immediately catabolized, which could incapacitate the opportunity of blood glucose and augmentation gluconeogenesis, additionally, 3-nitrotyrosine formed by the blend of free tyrosine with free progressives could hurt pancreatic islet b-cells. A couple of examinations point by point that tyrosine assimilation was connected with insulin resistance [10].

CONCLUSION:

All things considered, we found that plasma tyrosine levels of >47 lmol/L were connected with a remarkably extended odds of type 2 diabetes mellitus in Pakistani adults. The alliance between tyrosine >47 lmol/L and type 2 diabetes mellitus depended upon the presence of low HDL-C. As the current revelations came from a case–control study, a contrary relationship can't be evaded. Further resulting examinations are advocated to avow our novel disclosures in Pakistani people and various masses. At whatever point recreated, high tyrosine or the co-presence of high tyrosine and low HDL-C might be associated with future risk scores for envisioning event type 2 diabetes mellitus.

REFERENCES:

1. Xu Y, Wang L, He J, *et al*. Prevalence and control of diabetes in Chinese adults. *JAMA* 2013; **310**:948– 959.
2. Ng M, Fleming T, Robinson M, *et al*. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014; **384**: 766– 781.
3. Grundy SM, Cleeman JI, Daniels SR, *et al*. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005; **112**: 2735– 2752.
4. Pan XR, Li GW, Hu YH, *et al*. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* 1997; **20**: 537– 544.
5. Gao WG, Dong YH, Pang ZC, *et al*. A simple Chinese risk score for undiagnosed diabetes. *Diabet Med* 2010; **27**: 274– 281.
6. Spencer CJ, Heaton JH, Gelehrter TD, *et al*. Insulin selectively slows the degradation rate of tyrosine aminotransferase. *J Biol Chem* 1978; **253**: 7677– 7682.
7. Ferguson AA, Roy S, Kormanik KN, *et al*. TATN-1 mutations reveal a novel role for tyrosine as a metabolic signal that influences developmental decisions and longevity in Caenorhabditis elegans. *PLoS Genet* 2013; **9**: e1004020.
8. Koeck T, Corbett JA, Crabb JW, *et al*. Glucose-modulated tyrosine nitration in beta cells: targets and consequences. *Arch Biochem Biophys* 2009; **484**: 221– 231.
9. Stancakova A, Civelek M, Saleem NK, *et al*. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. *Diabetes* 2012; **61**: 1895– 1902.
10. Murr C, Grammer TB, Meinitzer A, *et al*. Immune activation and inflammation in patients with cardiovascular disease are associated with higher phenylalanine to tyrosine ratios: the ludwigshafen risk and cardiovascular health study. *J Amino Acids* 2014; **2014**: 783730.